Having trouble accessing articles? Reset your cache.

Asunaprevir: Additional Phase II data

Data from 16 treatment-naïve, non-cirrhotic patients with HCV genotype 1 infection in Part 1 of an open-label, international Phase II trial showed that an oral regimen of asunaprevir, daclatasvir and BMS-791325 for 24 weeks produced an SVR defined as undetectable

Read the full 401 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers